UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Volltextzugriff (PDF)

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226

2022

Volltextzugriff (PDF)

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Breast cancer research : BCR, 2019-12, Vol.21 (1), p.143-143, Article 143

2019

Volltextzugriff (PDF)

Molecular pathways: autophagy in cancer--a matter of timing and context

Clinical cancer research, 2015-02, Vol.21 (3), p.498-504

2015

Volltextzugriff (PDF)

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2804-2811

2018

Volltextzugriff (PDF)

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Genes & development, 2011-03, Vol.25 (5), p.460-470

2011

Volltextzugriff (PDF)

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution’s experience in Korea

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.653-663

2021

Volltextzugriff (PDF)

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Genes & development, 2007-07, Vol.21 (13), p.1621-1635

2007

Volltextzugriff (PDF)

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD5-03-PD5-03

2020

Volltextzugriff (PDF)

Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells

Breast cancer research and treatment, 2015-05, Vol.151 (1), p.57-73

2015

Volltextzugriff (PDF)

Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

The journal of pathology. Clinical research, 2024-05, Vol.10 (3), p.e12371-n/a

2024

Volltextzugriff (PDF)

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A364-A364

2021

Volltextzugriff (PDF)

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Cancer research (Chicago, Ill.), 2008-06, Vol.68 (11), p.4105-4115

2008

Volltextzugriff (PDF)

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

The New England journal of medicine, 2022-02, Vol.386 (6), p.556-567

2022

Volltextzugriff (PDF)

Chapter 4 A Mouse Mammary Epithelial Cell Model to Identify Molecular Mechanisms Regulating Breast Cancer Progression

Methods in Enzymology, 2008, Vol.446, p.61-76

2008

Volltextzugriff (PDF)

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (24), p.5427-5434

2020

Volltextzugriff (PDF)

Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Molecular cancer research, 2009-09, Vol.7 (9), p.1487-1496

2009

Volltextzugriff (PDF)

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Clinical cancer research, 2021-06, Vol.27 (11), p.3061-3068

2021

Volltextzugriff (PDF)

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT069-CT069

2017

Volltextzugriff (PDF)

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.653

2021

Volltextzugriff (PDF)

Association between event-free survival and overall survival in early-stage triple-negative breast cancer

Future oncology (London, England), 2024-02, Vol.20 (6), p.335-348

2024

Volltextzugriff (PDF)

Chapter 4 Assessing Metabolic Stress and Autophagy Status in Epithelial Tumors

Methods in Enzymology, 2009, Vol.453, p.53-81

2009

Volltextzugriff (PDF)

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-01-PS12-01

2021

Volltextzugriff (PDF)

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-30-01-OT-30-01

2021

Volltextzugriff (PDF)

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Annals of oncology, 2022-07, Vol.33, p.S465

2022

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

Zeitschrift / SerieJournal Of Clinical Oncology

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(53)

Publikationsform

Artikel
(57)
Buchkapitel
(2)

Sprache

Englisch
(59)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(18)
Oncology
(17)
Animals
(14)
Female
(14)
Breast Cancer
(12)
Mice
(10)
Cancer Therapies
(9)
Chemotherapy
(8)
Patients
(8)
Tumors
(8)
Middle Aged
(7)
Adult
(6)
Aged
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Monoclonal Antibodies
(6)
Targeted Cancer Therapy
(6)
Triple Negative Breast Neoplasms - Drug Therapy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pembrolizumab for Early Triple-Negative Breast Cancer

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Molecular pathways: autophagy in cancer--a matter of timing and context

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution’s experience in Korea

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells

Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Chapter 4 A Mouse Mammary Epithelial Cell Model to Identify Molecular Mechanisms Regulating Breast Cancer Progression

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive

Association between event-free survival and overall survival in early-stage triple-negative breast cancer

Chapter 4 Assessing Metabolic Stress and Autophagy Status in Epithelial Tumors

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Aktive Filter

Suchergebnisse filtern